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Abstract
Autism spectrum disorder (ASD) is a common, highly heritable neuro-developmental condition 
characterized by marked genetic heterogeneity1–3. Thus, a fundamental question is whether autism 
represents an etiologically heterogeneous disorder in which the myriad genetic or environmental 
risk factors perturb common underlying molecular pathways in the brain4. Here, we demonstrate 
consistent differences in transcriptome organization between autistic and normal brain by gene co-
expression network analysis. Remarkably, regional patterns of gene expression that typically 
distinguish frontal and temporal cortex are significantly attenuated in the ASD brain, suggesting 
abnormalities in cortical patterning. We further identify discrete modules of co-expressed genes 
associated with autism: a neuronal module enriched for known autism susceptibility genes, 
including the neuronal specific splicing factor A2BP1/FOX1, and a module enriched for immune 
genes and glial markers. Using high-throughput RNA-sequencing we demonstrate dysregulated 
splicing of A2BP1-dependent alternative exons in ASD brain. Moreover, using a published autism 
GWAS dataset, we show that the neuronal module is enriched for genetically associated variants, 
providing independent support for the causal involvement of these genes in autism. In contrast, the 
immune-glial module showed no enrichment for autism GWAS signals, indicating a non-genetic 
etiology for this process. Collectively, our results provide strong evidence for convergent 
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molecular abnormalities in ASD, and implicate transcriptional and splicing dysregulation as 
underlying mechanisms of neuronal dysfunction in this disorder.
We analyzed post-mortem brain tissue samples from 19 autism cases and 17 controls from 
the Autism Tissue Project and the Harvard brain bank (Supplementary Table1) using 
Illumina microarrays. For each individual, we profiled three regions previously implicated in 
autism5: superior temporal gyrus (STG /Brodmann’s area [BA] 41/42), prefrontal cortex 
(BA9) and cerebellar vermis. After filtering for high-quality array data (Methods), we 
retained 58 cortex samples (29 autism, 29 controls) and 21 cerebellum samples (11 autism, 
10 controls) for further analysis (see Methods for detailed sample description). We identified 
444 genes showing significant expression changes in autism cortex samples (DS1, Figure 
1b), and only 2 genes differentially expressed (DE) between the autism and control groups 
in cerebellum (Methods), indicating that gene expression changes associated with autism 
were more pronounced in cerebral cortex, which became the focus of further analysis 
(Supplementary Table 2). There was no significant difference in age, post mortem interval 
(PMI), or RNA integrity numbers (RIN) between autism and control cortex samples 
(Supplementary Figure 1, Methods).
Supervised hierarchical clustering based on the top 200 DE genes showed distinct clustering 
of the majority of autism cortex samples (Figure 1a), including one case that was 
simultaneously found to have a 15q duplication (Methods, Supplementary Table 1), which is 
known to cause 1% of ASD6. Cortex samples from ten of the cases coalesced in a single 
tight-clustering branch of the dendrogram. Clustering was independent of age, sex, RIN, 
PMI, co-morbidity of seizures, or medication (Figure 1a; Supplementary Figure 2c). It is 
interesting to note that the 2 ASD cases that cluster with controls (Figure 1a) are the least 
severe cases, as assessed by global functioning (Supplementary Table 12). We observed a 
highly significant overlap between DE genes in frontal and temporal cortex (p = 10E-44; 
Figure 1b), supporting the robustness of the data and indicating that the autism-specific 
expression changes are consistent across these cortical areas. We also validated a cross 
section of the DE genes by RT-PCR and confirmed microarray-predicted changes in 83% of 
the genes tested (Methods, Supplementary Figure 2b). Gene ontology (GO) enrichment 
analysis (Methods) revealed that the 209 genes downregulated in autistic cortex were 
enriched for GO categories related to synaptic function, whereas the upregulated genes 
(N=235) showed enrichment for GO categories implicated in immune and inflammatory 
response (Supplementary Table 3).
To test whether these findings were replicable, and to further validate the results in an 
independent dataset, we obtained tissue from an additional frontal cortex region (BA44/45) 
from nine ASD cases and five controls (DS2; Supplementary Table 4). Three of the cases 
and all of the controls used for validation were independent from our initial cohort. Ninety-
seven genes were differentially expressed in BA44/45 in DS2, and 81 of these were also DE 
in our initial cohort (p=1.2E-93, hypergeometric test; Figure 1b, c). Remarkably, the 
direction of expression differences between autism and controls was the same as in the 
initial cohort for all but 2 of the 81 overlapping DE probes. Hierarchical clustering of DS2 
samples based on either the top 200 genes DE in the initial cohort or the 81 overlapping 
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genes showed distinct separation of cases from controls (Supplementary Figure 6). In 
addition, comparison of these DE results with another, smaller study of the STG in ASD7, 
revealed significant consistency at the level of DE genes, including down-regulation of 
DLX1 and AHI1 (Supplementary Table 5). Thus, DE analysis produced robust and highly 
reproducible results, warranting further refined analysis.
We next applied weighted-gene co-expression network analysis (WGCNA)8; 9 to integrate 
the expression differences observed between autistic and control cerebral cortex into a 
higher order, systems level context. We first asked whether there are global differences in 
the organization of the brain transcriptome between autistic and control brain by 
constructing separate co-expression networks for the autism and control groups (Methods). 
The control brain network showed high similarity with the previously described human 
brain co-expression networks (Supplementary Table 7), consistent with the existence of 
robust modules of co-expressed genes related to specific cell types and biological functions8. 
Similarly, the majority of the autism modules (87%) showed significant overlap with the 
previously described human brain modules (Supplementary Table 6), indicating that many 
features reflecting the general organization of the autism brain transcriptome are consistent 
with that of the normal human brain.
The expression levels of each module were summarized by the first principal component 
(the module eigengene), and were used to assess whether modules are related to clinical 
phenotypes or other experimental variables, such as brain region. Two of the control module 
eigengenes (cM6, cM13) showed significant differences (p<0.05) between the two cortical 
regions as expected, whereas none of the ASD modules showed any differences between 
frontal and temporal cortex. This led us to explore the hypothesis that the normal molecular 
distinctions between the two cortical regions tested were altered in ASD compared with 
controls. Remarkably, while 174 genes were DE between control BA9 and BA41 
(FDR<1%), none of the genes were DE in the same regional comparison among the ASD 
cases. This was not simply an issue of statistical thresholds, as relaxing the statistical criteria 
for DE to an FDR of 5%, identified over 500 DE genes in controls, and only 8 in ASD 
brains, confirming the large difference observed in regional cortical differential gene 
expression between ASD cases and controls (Figure 1d, Methods). Analysis of DE from a 
data set10 of gene expression in developing fetal human brain showed a highly significant (p 
= 5.8E-9) overlap of DE genes with those found in controls in this study, independently 
confirming that these genes differentiate normal temporal and frontal lobes. We evaluated 
the homogeneity of gene expression variance across the autism and control groups using 
Bartlett’s test (Methods) which indicated that increased variance was not the major factor 
responsible for the striking difference in regional gene expression between ASD and 
controls (Supplementary Figure 7 and Supplementary Data).
These data suggest that typical regional differences, many of which are observed during 
fetal development10, are attenuated in frontal and temporal lobe in autism brain, pointing to 
abnormal developmental patterning as a potential pathophsyiological driver in ASD. This is 
especially interesting in light of a recent anatomical study of 5 cases with adult autism which 
demonstrated a reduction in typical ultrastructural differences between 3 frontal cortical 
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regions in autism11. Together, these independent studies provide both molecular and 
structural evidence suggesting a relative diminution of cortical regional identity in autism.
To identify discrete groups of co-expressed genes showing transcriptional differences 
between autism and controls, we constructed a co-expression network using the entire 
dataset, composed of both autism and control samples (Methods). As previously shown for 
complex diseases12; 13 co-expression networks allow analysis of gene expression variation 
related to multiple disease-related and genetic traits. We assessed module eigengene 
relationship to autism disease status, age, gender, cause of death, co-morbidity of seizures, 
family history of psychiatric disease, and medication, providing a complementary 
assessment of these potential confounders to that performed in the standard DE analysis 
(Supplementary Table 9).
The comparison between autism and control groups revealed two network modules whose 
eigengenes were highly correlated with disease status, and not any of the potential 
confounding variables (Supplementary Table 9). We found that the top module (M12) 
showed highly significant enrichment for neuronal markers (Supplementary Table 9), and 
high overlap with two neuronal modules previously identified as part of the human brain 
transcriptional network8: a PVALB+ interneuron module and a module of genes involved in 
synaptic function. The M12 eigengene was under-expressed in autism cases, indicating that 
genes in this module were down-regulated in the autistic brain (Figure 2). Consistent with 
the pathways identified to be downregulated in autism by DE analysis (Supplementary Table 
3), the functional enrichment of M12 included the GO categories involved in synaptic 
function, vesicular transport and neuronal projection.
Remarkably, unlike DE genes, M12 showed significant overrepresentation of known autism 
susceptibility genes2 (Supplementary Table 10; p = 6.1E-4), including CADPS2, AHI1, 
CNTNAP2, and SLC25A12, supporting the increased power of the network-based approach 
to identify disease-relevant transcriptional changes. A further advantage of network analysis 
over standard analysis of DE is that it allows one to infer the functional relevance of genes 
based on their network position9. The hubs of M12, i.e. the genes with the highest rank of 
M12 membership8, were A2BP1, APBA2, SCAMP5, CNTNAP1, KLC2, CHRM1 
(Supplementary Data). The first three of these genes have previously been implicated in 
autism14–16, while the fourth is a homologue of the autism susceptibility gene CNTNAP217. 
We highlight the group of genes most strongly connected to the known ASD genes 
(Supplementary Figure 5) and emphasize the down-regulation of several interneuron 
markers, such as DLX1 and PVALB, as candidates for future genetic and pathologic 
investigations.
The second module of co-expressed genes highly related to autism disease status, M16, was 
enriched for astrocyte markers and markers of activated microglia (Supplementary Table 9), 
as well as for genes belonging to immune and inflammatory GO categories (Figure 2). This 
module, which was upregulated in ASD brain, showed significant similarity to two modules 
identified in previous studies of normal human brain8: an astrocyte module and a microglial 
module. Consistent with this functional annotation, two of the hubs of the M16 module were 
known astrocyte markers (ADFP and IFITM2).
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One of the hubs of the M12 module was A2BP1/FOX1, a neural- and muscle-specific 
alternative splicing regulator18 and the only splicing factor previously implicated in ASD16. 
Since A2BP1 was down-regulated in several ASD cases (Supplementary Figure 8), this 
observation provided a unique opportunity to identify potential disease relevant A2BP1 
targets. While A2BP1-regulated alternative exons have been predicted genome-wide19, few 
genes have been experimentally validated as A2BP1 targets20. To identify potential A2BP1-
dependent differential splicing (DS) events in ASD brain, we performed high-throughput 
RNA sequencing (RNA-Seq) on 3 autism samples with significant down-regulation of 
A2BP1 (average fold change by qRT-PCR: 5.9) and 3 control samples with average A2BP1 
levels. We identified 212 significant alternative splicing events (Supplementary Data). 
Among these, 36 had been defined by Zhang et al.19 as predicted targets of A2BP1/2, which 
represents a highly significant overlap (p=2.2E-16). In addition, five previously validated 
A2BP1 targets showed evidence of alternative splicing, four of which (ATP5C1, ATP2B1, 
GRIN1 and MEF2C) were confirmed as having differential splicing between ASD samples 
with low A2BP1 expression and control samples, indicating that we were able to identify a 
high proportion of the expected A2BP1-dependent DS events. We also observe that 
alternative exons with increased skipping in ASD relative to control cases are significantly 
enriched for A2BP1 motifs in adjacent, downstream intronic sequences (p = 1.09E-7, Fisher 
exact test), consistent with previous data19.
The top GO categories enriched among ASD DS genes highly overlapped with the GO 
categories found to be enriched in the M12 module (Figure 3b). In addition, A2BP1 target 
genes showed enrichment for actin-binding proteins and genes involved in cytoskeleton re-
organization (Figure 3b). Among top predicted A2BP1-dependent DS events (Figure 3a) are 
CAMK2G, which also belongs to the M12 module, as well as NRCAM and GRIN1. The 
latter are proteins involved in synaptogenesis, in which allelic variants have been associated 
with autism and schizophrenia respectively21; 22.
RT-PCR assays confirmed a high proportion (85%) of the tested DS changes involving 
predicted A2BP1 targets (Supplementary Figure 8). We further tested the DS events 
validated by RT-PCR in 3 independent ASD cases with decreased A2BP1 levels and 
confirmed the predicted changes in alternative splicing (Supplementary Figure 8), indicating 
that the observed DS events are indeed associated with reduced A2BP1 levels, rather than 
due to inter-individual variability. The RNA-Seq data thus provides validation of the 
functional groups of genes identified by co-expression analysis, and evidence for a 
convergence of transcriptional and alternative-splicing abnormalities in the synaptic and 
signaling pathogenesis of ASD.
To test whether our findings are more generalizable, and determine whether the autism-
associated transcriptional differences observed are likely to be causal, versus collateral 
effects or environmentally-induced changes, we tested whether our co-expression modules 
or the DE genes show enrichment for autism genetic association signals. M12 showed 
highly significant enrichment for association signals (p = 5E-4), but neither M16 nor the list 
of DE genes showed such enrichment (Figure 4). As a negative control, we performed the 
same set-enrichment analysis using two GWAS studies for non-psychiatric disease 
performed on the same genotyping platform: a genome-wide association for hair color23, 
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and a GWAS study of Warfarin maintenance dose24 finding no significant enrichment of the 
association signal (Figure 4b, Supplementary Figure 4). These results indicate that (a) M12 
consists of a set of genes that are supported by independent lines of evidence to be causally 
involved in ASD pathophysiology, and (b) the upregulation of immune response genes in 
the autistic brain observed by us and others25 has no evidence of a common genetic 
component.
Our system-level analysis of the ASD brain transcriptome demonstrates the existence of 
convergent molecular abnormalities in ASD for the first time, providing a molecular 
neuropathological basis for the disease, whose genetic, epigenetic, or environmental 
etiologies can now be directly explored. The genome-wide analysis performed here 
significantly extends previous findings implicating synaptic dysfunction, as well as 
microglial and immune dysregulation in ASD6 by providing an unbiased systematic 
assessment of transcriptional alterations and their genetic basis. We show that the 
transcriptome changes observed in ASD brain converge with GWAS data in supporting the 
genetic basis of synaptic and neuronal signaling dysfunction in ASD, while immune changes 
have a less pronounced genetic component and thus are most likely either secondary 
phenomena or caused by environmental factors. Since immune molecules and cells such as 
microglia play a role in synaptic development and function26, we speculate that the observed 
immune up-regulation may be related to abnormal ongoing plasticity in ASD brain. The 
striking attenuation of gene expression differences observed here between frontal and 
temporal cortex in ASD likely represents a defect of developmental patterning and provides 
a strong rationale for further studies to assess the pervasiveness of transcriptional patterning 
abnormalities across the ASD brain. We also demonstrate for the first time alterations in 
differential splicing associated with A2BP1/FOX1 levels in ASD brain, and show that many 
of the affected exons belong to genes involved in synaptic function. Finally, given current 
evidence of genetic overlap between ASD and other neurodevelopmental disorders 
including schizophrenia and ADHD, our data provide a new pathway-based framework from 
which to assess the enrichment of genetic association signals in other psychiatric disorders.
METHODS SUMMARY
Brain Tissue
Postmortem brain tissue was obtained from the Autism Tissue Project and the Harvard Brain 
Bank as well as the MRC London Brain bank for Neurodegenerative Disease. Detailed 
information on the autism cases included in this study is available in Methods.
Microarrays and RNAseq
Total RNA was extracted from 100 mg of tissue using a Qiagen miRNA kit according to the 
manufacturer’s protocol. Expression profiles were obtained using Illumina Ref 8 v3 
microarrays. RNAseq was performed on the Illumina GAIIx, as per the manufacturer’s 
instructions. Furthere detailed information on data analysis is available in Methods. All 
microarray and RNAseq data is deposited in GEO under accession numbers which are 
pending.
Full detailed Methods accompany this paper as supplemental material.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Gene expression changes in autism cerebral cortex
A. Heatmap of top 200 genes differentially expressed between autism and control cortex 
samples. Scaled expression values are color-coded according to the legend on the left. The 
dendrogram depicts hierarchical clustering based on the top 200 DE genes. The top bar 
(A/C) indicates the disease status: red-autism, black-control. The bottom bars show 
additional variables for each sample: sex (grey-male, black-female), brain area (black-
temporal, grey-frontal), co-morbidity of seizures (green-autism case with seizure disorder, 
red-autism case without seizure disorder, black-control), age, RNA integrity number (RIN) 
and post mortem interval (PMI). The corresponding scale for quantitative variables is shown 
on the left.
B. Top: Venn diagram depicting the overlap between genes DE in frontal and temporal 
cortex. Bottom: Venn diagram describing the overlap between genes DE in the initial cohort 
(DS1) and the replication cohort (DS2). Differential expression in the initial cohort was 
assessed at an FDR<0.05 and fold changes>1.3. The statistical criteria were relaxed to 
p<0.05 for the replication dataset since it involved fewer samples.
C. Expression fold changes for all genes DE in the initial cohort are plotted on the x-axis 
against the fold changes for the same genes in the replication cohort on the y-axis. Green-
genes downregulated in the autism group in both datasets, red-genes upregulated in the 
autism group in both datasets, grey-genes with opposite direction of variation in the two 
datasets. Horizontal lines show fold change threshold for significance.
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D. (left) Diagram depicting the number of genes showing significant expression differences 
between frontal and temporal cortex in control samples (top) and autism samples (bottom) at 
FDR<0.05. (right) Top 20 genes differentially expressed between frontal and temporal 
cortex in control samples. All of the genes shown are also differentially expressed between 
frontal and temporal cortex in fetal midgestation brain10, but show no significant expression 
differences between frontal and temporal cortex in autism. The horizontal bars depict p 
values for differential expression between frontal and temporal cortex in the autism and 
control groups.
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Figure 2. Gene co-expression modules associated with autism
A, D Top-heatmap of genes belonging to the co-expression module. Bottom-corresponding 
module eigengene values (y-axis) across samples (x-axis) . Red-autism, grey-controls.
B, E Visualization of the M12 and M16 modules respectively. The top 150 connections are 
shown for the each module. Genes with the highest correlation with the module eigengene 
value (i.e intramodular hubs) are shown in larger size.
C, F Relevant gene ontology categories enriched in the M12 and M16 modules
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Figure 3. A2BP1-dependent differential splicing events
A. Top A2BP1-specific differential splicing events. DS events showing the most significant 
differences in alternative splicing between low-A2BP1 autism cases and controls as well as 
DS differences consistent with the A2BP1 binding site position. The horizontal axis depicts 
the percentage of transcripts including the alternative exon. Red-autism samples, black-
control samples.
B. Relevant gene ontology categories enriched in the set of genes containing exons 
differentially spliced between low-A2BP1 autism cases and controls.
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Figure 4. GWAS set enrichment analysis
A. GWAS set enrichment analysis using the discovery AGRE cohort from Wang et al.27 For 
each gene set (DE genes, M12 and M16) the null distribution of the enrichment score 
generated by 10000 random permutations is shown (x-axis) and the enrichment score for the 
gene set is depicted by a red vertical line. A p value < 0.01 was considered significant to 
correct for multiple comparisons.
B. GWAS signal enrichment of DE genes and the autism-associated co-expression modules 
M12 and M16. Enrichment p values are shown for an autism GWAS dataset (Wang et al.27, 
AGRE discovery cohort) as well as two control datasets consisting of GWAS studies of non-
psychiatric traits: Han et al.23 (Negative control 1) and Cooper et al.24 (Negative control 2). 
The red line marks the p value threshold for significance.
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